Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Barry Paul, Myra Robinson, James Symanowski, David M Foureau, Sarah Norek, Manisha Bhutani, Christopher Ferreri, Ami P Ndiaye, Jordan Robinson, Shebli Atrash, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, April Smith, Jessica Duda, Lance Cooper, Amani Kitali, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2024-208830

Published: 2024

Journal Articles

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Jordan Snyder, Jessica McElwee, Hailey Hill, Donald C Moore, Shebli Atrash, Myra Robinson, Ferdous Ahmed, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Grace Elsey

Blood (2024) 144 (Supplement 1): 7845.

https://doi.org/10.1182/blood-2024-208961

Published: 2024

Journal Articles

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Semegne Hiruy, Myra Robinson, Shebli Atrash, Barry Paul, Reed Friend, Cindy Varga, Christopher J Ferreri, Mauricio Pineda-Roman, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 3769.

https://doi.org/10.1182/blood-2024-202137

Published: 2024

Journal Articles

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Darryl Chang, Myra Robinson, Rupali Bose, Hamid Ehsan, Arunkumar Krishnan, Shanice Borden, Peter M. Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Christopher Ferreri, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2024-209358

Published: 2024

Journal Articles

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Semaje Testamark, Allison Verbyla, Myra Robinson, Peter M. Voorhees, Manisha Bhutani

Blood (2023) 142 (Supplement 1): 1977.

https://doi.org/10.1182/blood-2023-175032

Published: 2023

Journal Articles

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Hamid Ehsan, Myra Robinson, Patrick Meadors, Rushil Patel, Shanice Borden, Peter M. Voorhees, Delcan Walsh, Barry Paul, Manisha Bhutani, Cindy Varga, Shebli Atrash

Blood (2023) 142 (Supplement 1): 7416.

https://doi.org/10.1182/blood-2023-178114

Published: 2023

Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani

Blood (2023) 142 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2023-174972

Published: 2023

Journal Articles

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Ifeyinwa Osunkwo, Myra Robinson, Anya Griffin, Azizi Coleman, Sharvil Desai, Padmaja Veeramreddy, Payal Desai, Charity Patterson, James Symanowski, Paulette Bryant, Jennifer Cornette, Wally R Smith, James R Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2023-186835

Published: 2023

Journal Articles

Implementing a Structured Health Care Transition (HCT) Process for Sickle Cell Disease Using Quality Improvement: Results from the Sickle Cell Trevor Thompson Transition Project HCT Learning Collaborative

Ifeyinwa Osunkwo, Jennifer Cornette, Cheryl Courtlandt, Myra Robinson, Patience White, Margaret McManus, Laura Noonan, Payal Desai, Charity Patterson, James R. Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 248.

https://doi.org/10.1182/blood-2023-187815

Published: 2023

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Srinivasa Reddy Sanikommu, Shebli Atrash, Myra Robinson, Nury M. Steuerwald, Kristen Cassetta, Hsih-Te Yang, Saad Usmani, Edward A. Copelan, Belinda R. Avalos, Lawrence J. Druhan

Blood (2022) 140 (Supplement 1): 11416–11417.

https://doi.org/10.1182/blood-2022-170887

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani

Blood (2021) 138 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2021-148508

Published: 2021

Journal Articles

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Heather Cranford, CPhT, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136578

Published: 2020

Journal Articles

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Barry Paul, MDMS, Myra Robinson, MSPH, Kristen Cassetta, Daniel Slaughter, Jordan Robinson, Ami P Ndiaye, NP, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA, Shebli Atrash, MD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-141637

Published: 2020

Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141562

Published: 2020

Journal Articles

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137222

Published: 2020

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

NARROW

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Implementing a Structured Health Care Transition (HCT) Process for Sickle Cell Disease Using Quality Improvement: Results from the Sickle Cell Trevor Thompson Transition Project HCT Learning Collaborative

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only